Schrödinger
120 West 45th Street
17th Floor
New York
NY
10036-4041
United States
Tel: 503-299-1150
Website: https://www.schrodinger.com/careers
Email: careers@schrodinger.com
149 articles about Schrödinger
-
Schrödinger to Host Second Quarter 2020 Financial Results Conference Call and Webcast
8/3/2020
Schrödinger, whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and materials, announced that it will host a conference call and webcast on Monday, August 10, 2020 at 8:30 a.m. ET to discuss second quarter 2020 financial results and provide a general business update.
-
Schrödinger and Viva Biotech Announce Strategic Collaboration to Generate and Interrogate Structures for Unsolved Targets
7/28/2020
Collaboration aims to enable discovery of first-in-class therapeutic candidates
-
Schrödinger Expands Discovery Efforts for COVID-19 Alliance with Advanced Molecular Simulation Leveraging High-Powered Parallel Computing on Google Cloud
6/23/2020
Schrödinger, whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and materials, announced a significant expansion of its work to discover novel antiviral therapeutics for COVID-19 as a part of a philanthropic global initiative.
-
Schrödinger Announces Strategic Collaboration With Thermo Fisher Scientific to Expand Structure-Based Drug Discovery to Novel Targets Using Cryo-EM
6/23/2020
Schrödinger announced a strategic collaboration with Thermo Fisher Scientific to extend the use of cryo-EM in connection with in silico compound screening to accelerate drug discovery.
-
Schrödinger to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
6/16/2020
Schrödinger (Nasdaq: SDGR), whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and materials, today announced that members of the management team will participate in a fireside chat at the BMO 2020 Prescriptions for Success Healthcare Conference at 2:30 p.m. ET on Tuesday, June 23, 2020. A live webcast of the presentation can be accessed under "News & Events" in th
-
Schrödinger to Present at the Jefferies 2020 Virtual Healthcare Conference
5/28/2020
Schrödinger, whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and materials, announced that members of the management team will participate in a fireside chat at the Jefferies 2020 Virtual Healthcare Conference at 3:00 p.m. ET on Thursday, June 4, 2020.
-
Schrödinger Reports First Quarter 2020 Financial Results and Recent Business Updates
5/13/2020
Total revenue of $26.2 million and strong growth of 26% year-over-year Record software revenue of $23.8 million, up 28% year-over-year Raised $209.6 million in net proceeds through initial public offering Conference call today, Wednesday, May 13, 2020 at 8:30 a.m. ET NEW YORK--( BUSINESS WIRE )-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform enables discovery of high-quality, novel molecules for therapeu
-
BioSpace Movers & Shakers, May 8
5/8/2020
Pharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Schrödinger to Host First Quarter 2020 Financial Results Conference Call and Webcast
5/6/2020
Schrödinger, whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and materials, announced that it will host a conference call and webcast on Wednesday, May 13, 2020 at 8:30 a.m. ET to discuss first quarter 2020 financial results and provide a general business update.
-
Schrödinger Strengthens Board of Directors with Appointments of Jeffrey Chodakewitz, M.D., and Gary Ginsberg
5/4/2020
Schrödinger, whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and materials, announced the appointments of Jeffrey A. Chodakewitz, M.D., and Gary Ginsberg to its Board of Directors.
-
Schrödinger Announces Expanded Collaboration with AstraZeneca to Extend Computational Modeling Solutions to Biologics
3/23/2020
Schrödinger announced an expanded collaboration with AstraZeneca focused on refining a biologics modeling solution with the aim of speeding up the development of antibody and protein-based therapeutic candidates.
-
Schrödinger Taps Google Cloud’s High-Performance Compute (HPC) Solution to Bolster Its Drug Discovery Efforts
3/2/2020
Three-year deal will enable broader chemical exploration and accelerate advanced molecular modeling across internal and collaborative programs
-
Schrödinger Announces Closing of Initial Public Offering
2/10/2020
Schrödinger, Inc. announced the closing of its initial public offering of 13,664,704 shares of common stock at a public offering price of $17.00 per share, which includes 1,782,352 additional shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares, for total gross proceeds of approximately $232.3 million, before underwriting discounts and commissions and offering expenses payable by the Company.
-
Schrödinger Announces Pricing of Initial Public Offering at $17.00 per share
2/6/2020
Schrödinger, Inc. announced the pricing of its initial public offering of 11,882,352 shares of common stock at a public offering price of $17.00 per share, for total gross proceeds of approximately $202.0 million, before underwriting discounts and commissions and offering expenses payable by the Company.
-
Twist Bioscience Announces Strategic Collaboration With Schrödinger for Drug Discovery
1/15/2020
Under the terms of the agreement, each company will contribute their individual expertise in a highly collaborative manner to discover novel antibody therapeutics
-
Schrödinger Appoints Drug Discovery Veteran Nancy Thornberry to Board of Directors
9/24/2019
Schrödinger announced the appointment of Nancy Thornberry, a biotech executive recognized for her extensive track record in drug discovery and development, to its Board of Directors.
-
The importance of artificial intelligence and machine learning is ever-increasing in the world of drug development and AstraZeneca is bolstering its participation in the tech revolution by striking a deal with New York-based Schrodinger to use that company’s advanced computing platform to help ac...
-
Schrödinger Announces Expansion of Multi-Target Research Collaboration with Takeda and Achievement of First Significant Preclinical Milestone in Lead Program
9/5/2019
Schrödinger announced the expansion of its multi-year, multi-target drug discovery collaboration with Takeda, as well as Schrödinger’s achievement of the first significant preclinical milestone for the collaboration’s most advanced program.
-
Schrödinger Announces Collaboration with AstraZeneca to Deploy Advanced Computing Technology for Drug Discovery
9/4/2019
Schrödinger announced a collaboration with AstraZeneca to deploy Schrödinger’s advanced computing platform to help accelerate drug discovery efforts.
-
Schrödinger and Qu & Co Announce Collaboration to Advance Quantum Mechanical Computations on Quantum Computers
9/3/2019
Schrödinger and Qu & Co announced a business and scientific collaboration to advance the use of quantum mechanics on complex molecular systems using quantum computing hardware.